

## FACULTY DISCLOSURES

Consultant/Member of Advisory Board: Jacquelyn L. Bainbridge (Teva), L. Brian Cross (AstraZeneca), Shellee A. Grimm (Astellas Pharma, Inc.)

Grant Funding/Research Support: Jacquelyn L. Bainbridge (UCB Pharma, NIH), Michael P. Kane (Bristol-Myers Squibb)

Speaker's Bureau: Jacquelyn L. Bainbridge (UCB Pharma), Michael P. Kane (Boehringer Ingelheim, Eli Lilly)

Other: Mary Ann Kliethermes (co-owner of Clinical Pharmacy Systems, Inc.)

Nothing to Disclose: Katie E. Cardone, Alicia B. Forinash, Adam B. Jackson, William A. Kehoe, Mary Ann Kliethermes, Daniel S. Longyhore, Michelle T. Martin, Jamie L. McConaha, Emily McCoy, Jean Y. Moon, Kevin M. Sowinski, Jessica Tilton, Joseph P. Vande Griend, Orly Vardeny

## REVIEWER DISCLOSURES

Consultant/Member of Advisory Board: Sara E. Dugan (Minds Matter and MOMS [Maternal Opiate Medical Support]), Elizabeth Sebranek Evans (VRX)

Received Grant Funding/Research Support: Sara E. Dugan (Northeast Ohio Medical University [NEOMED] Best Practices in Schizophrenia Treatment [BeST] Center, Medicaid Technical Assistance and Policy Program [MEDTAPP])

Reviewers not listed above have nothing to disclose.